Patents Assigned to Inserm
  • Dipeptidylpeptidase 4 inhibition enhances lymphocyte trafficking, improving both naturally occurring tumor immunity and immunotherapy
    Patent number: 11229645
    Abstract: The success of anti-tumor immune responses requires effector T cells to infiltrate solid tumors, a process guided by chemokines. Herein, we demonstrate that in vivo post-translational processing of chemokines by dipeptidylpeptidase 4 (DPP4, also known as CD26) limits lymphocyte migration to sites of inflammation and tumors. Inhibition of DPP4 enzymatic activity enhanced tumor rejection by preserving biologically active CXCL10, and increasing trafficking into the tumor by lymphocytes expressing the counter-receptor CXCR3. Furthermore, DPP4 inhibition improved adjuvant-based immunotherapy, adoptive T cell transfer and checkpoint blockade. These findings provide the first direct in vivo evidence for controlling lymphocyte trafficking through CXCL10 cleavage and support the use of DPP4 inhibitors for stabilizing the biologically active form of chemokines as a strategy to enhance tumor immunotherapy.
    Type: Grant
    Filed: May 12, 2020
    Date of Patent: January 25, 2022
    Assignees: INSTITUT PASTEUR, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Rosa Barreira Da Silva, Matthew Albert
  • Biomarker of the colour perception of a mammal subject based on pupil frequency tagging
    Patent number: 11229356
    Abstract: Evaluation of the perception of colors by mammals with a view to obtaining a characteristic biomarker of each tested subject takes advantage of the slow pupillary oscillatory response to generate an objective neurological signature of this perception of colors. A method based on pupil frequency tagging is used at a tagging frequency Ftag adapted to the pupil response speed. A dynamic two-color stimulus is displayed, this stimulus comprising a two-color pattern the colors of which are inverted at the frequency Ftag, one of the colors gradually varying in a range of possible values. From the pupillary response, a signal representative of the oscillation power of the pupil is generated. The minimum of this signal corresponds to the relative iso-luminance of the tested pair of colors.
    Type: Grant
    Filed: March 29, 2018
    Date of Patent: January 25, 2022
    Assignees: INSTITUT DU CERVEAU ET DE LA MOELLE EPINIERE (ICM), CENTRE NATIONAL DE LA RACHERCHE SCIENTIFIQUE (CNRS), INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS (AP-HP), SORBONNE UNIVERSITE
    Inventors: Pierre Pouget, Pierre Daye, Jean Lorenceau
  • Methods for assessing pregnancy outcome
    Patent number: 11230736
    Abstract: The invention relates to a method of assessing pregnancy outcome. The inventors investigated endometrial miRNAs associated with pregnancy outcome by studying miRNAs associated with endometrial receptivity, implantation failure and embryo miscarriage. They performed a miRNomic study to find miRNAs that are differentially expressed according to the endometrial receptivity status, compared the endometrial miRNome between receptive patients with negative beta-hCG and receptive patients with positive beta-hCG, and compared the endometrial miRNome between receptive patients with a miscarriage between 8-12 weeks of amenorrhoea and receptive patients with a live birth. They demonstrated miRNA differential expression in endometrial samples according to the pregnancy outcome.
    Type: Grant
    Filed: March 28, 2018
    Date of Patent: January 25, 2022
    Assignees: INSERM (Institut National de la Santé de la Recherche Médicale), Université de Montpellier, Centre Hospitalier Universitaire de Montpellier
    Inventors: Samir Hamamah, Delphine Haouzi
  • Methods and kits for predicting the risk of having or developping hepatocellular carcinoma in patients suffering from cirrhosis
    Patent number: 11231422
    Abstract: Plasma levels of different sub-populations of microvesicles (endothelial, leukocyte, platelet and hepatocyte) were measured by flow cytometry or ELISA/filtration on blood samples from 125 patients with cirrhosis, for which 36 of them were diagnosed with HCC at inclusion. The inventors show that the levels of microvesicles of endothelial origin (CD62E+) could predict the occurrence of HCC in patients with cirrhosis. Therefore the present invention relates to a method for determining whether a patient suffering from cirrhosis is at risk of having or developing hepatocellular carcinoma comprising determining the level of endothelial-derived microvesicles (e.g. by flow cytometry) in a blood sample obtained from the patient.
    Type: Grant
    Filed: March 20, 2018
    Date of Patent: January 25, 2022
    Assignees: INSERM (Institut National de la Santé et de la Recherche Médicale), Université Paris Descartes, Assistance Publique Hôpitaux de Paris (APHP), UniversitéParis Diderot—Paris 7
    Inventors: Pierre-Emmanuel Rautou, Chantal Boulanger-Robert
  • Xanthine derivative inhibitors of BET proteins
    Patent number: 11225481
    Abstract: This invention relates to xanthine derivative compounds that are inhibitors of BET bromodomains proteins, the method of preparation thereof and applications thereof.
    Type: Grant
    Filed: December 27, 2016
    Date of Patent: January 18, 2022
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITÉ D'AIX-MARSEILLE, INSTITUT JEAN PAOLI & IRENE CALMETTES
    Inventors: Xavier Morelli, Sébastien Combes, Jean-Claude Guillemot, Stéphanie Betzi, Yves Collette, Philippe Roche, Adrien Lugari, Sabine Milhas, Brigitt Raux, Iuliia Voitovich
  • Natural product derivatives for inhibiting cellular necroptosis, ferroptosis and oxytosis
    Patent number: 11224586
    Abstract: The present invention relates to a compound of the following general formula (I); or a pharmaceutically acceptable salt and/or solvate thereof, for use as drug, particularly intended for inhibiting a programmed cell death route selected from the group consisting of ferroptosis, oxytosis and cellular necroptosis. The present invention also relates to a compound of general formula (I) for use as a drug for neuroprotection as well as for preventing and/or treating disorders associated with cellular necroptosis or ferroptosis. The present invention also relates to a pharmaceutical composition comprising a compound of general formula (I), or a pharmaceutically acceptable salt and/or solvate thereof. The present invention also encompasses the use of a compound of the general formula (I) for organs preservation.
    Type: Grant
    Filed: October 18, 2017
    Date of Patent: January 18, 2022
    Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Centre National de la Recherche Scientifique (CNRS), Sorbonne Universite, Universite de Poitiers, Centre Hospitalier Universitaire de Poitiers
    Inventors: Stéphane Bach, Marie-Thérèse Dimanche-Boitrel, Claire Delehouze, Thierry Hauet
  • Methods and kits for diagnosing postoperative pulmonary infections in patients who underwent surgery
    Patent number: 11226343
    Abstract: The present invention relates to methods and kits for diagnosing a postoperative pulmonary infection in a patient who underwent surgery. More particularly, the present invention relates to a method for diagnosing a postoperative pulmonary infection in a patient who underwent surgery, comprising a step consisting of measuring the concentration of endocan in a blood sample obtained from said patient, at a time point comprised between 3 h and 30 h after surgery.
    Type: Grant
    Filed: April 7, 2017
    Date of Patent: January 18, 2022
    Assignees: BIOTHELIS, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LE RECHERCHE MEDICAL), INSTITUT PASTEUR DE LILLE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE—CNRS—, UNIVERSITE DE LILLE
    Inventors: Philippe Lasalle, Sidney Chocron, Nathalie De Freitas Caires
  • METHOD FOR DETERMINING ONE CONTENT IN PROTEIN AND ASSOCIATED DEVICES AND METHODS
    Publication number: 20220011217
    Abstract: A method for determining at least one protein in the blood which is more precise while still being simple to implement. The method exploits in an original way the spectroscopy and the dosing techniques to determine accurately the content in proteins of the biological sample, notably for oxyhemoglobin, methemoglobin, heme bound to serum albumin and hemopexin and bilirubin. Such method can advantageously be used in various applications concerning heme-related or hemoprotein-related disorders, notably method for diagnosing, for following a treatment, for determining biomarkers or for screening. Such a method is also interesting for qualifying blood bags.
    Type: Application
    Filed: November 29, 2019
    Publication date: January 13, 2022
    Applicants: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITÉ PARIS EST CRÉTEIL VAL DE MARNE, ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS
    Inventors: Laurent KIGER, Pablo BARTOLUCCI, Michael MARDEN
  • Methods and compositions for treating and preventing HIV
    Patent number: 11219683
    Abstract: Methods and compositions are provided that can be used to vaccinate against and treat HIV. Specifically contemplated are vaccine compositions and methods of using these compositions treat HIV in patients. Aspects of the disclosure relate to an anti-CD40 antibody-HIV antigen fusion protein comprising (i) an anti-CD40 heavy chain (HCD40)-HIV antigen (Ag) fusion protein comprising the formula: HCD40-Ag, wherein Ag is a polypeptide with at least 80% sequence identity to SEQ ID NO:1; and (ii) an anti-CD40 light chain (LCD40).
    Type: Grant
    Filed: June 19, 2020
    Date of Patent: January 11, 2022
    Assignees: INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE M{circumflex over (D)}DICALE (INSERM), UNIVERSITE PARIS EST CRETEIL VAL DE MARNE, ASSISTANCE PUBLIQUE HOPITAUX DE PARIS, BAYLOR RESEARCH INSTITUTE
    Inventors: Yves Levy, Gerard Zurawski, Sandra Zurawski, Anne-Laure Flamar
  • Anti-metastatic marine bacterial exopolysaccharide derivative and uses thereof
    Patent number: 11219638
    Abstract: The invention provides a low-molecular-weight (15 kDa) over-sulfated exopolysaccharide (GYS15) prepared from a marine native exopolysaccharide excreted by a mesophilic marine bacterium from a deep-sea hydrothermal environment, and relates to the use of this low-molecular-weight over-sulfated exopolysaccharide for the prevention or inhibition of metastases formation.
    Type: Grant
    Filed: September 28, 2016
    Date of Patent: January 11, 2022
    Assignees: INSTITUT FRANCAIS DE RECHERCHE POUR L'EXPLOITATION DE LA MER (IFREMER), UNIVERSITE DE NANTES, INSERM (Institut National de la Santé et de la Recherche Médicale), CENTRE HOSPITALIER UNIVERSITAIRE DE NANTES
    Inventors: Sylvia Colliec-Jouault, Corinne Sinquin, Jacqueline Ratiskol, Dominique Heymann, Carmen Ruiz-Velasco, Julie Chesneau
  • HAFNIA ALVEI FORMULATIONS
    Publication number: 20210401020
    Abstract: A composition essentially made of a Hafnia alvei probiotic strain expressing the ClpB protein; wherein the ClpB protein is in an amount of at least 0.7% (w/w) in weight relative to the total weight of the composition; and the ratio of the total number of Hafnia alvei Colony Forming Units to the total Hafnia alvei cell number ranges from 10?4 to 0.8. Also, oral dosage forms, namely gastro-resistant capsules including the composition of essentially made of a Hafnia alvei probiotic strain expressing the ClpB protein.
    Type: Application
    Filed: November 28, 2019
    Publication date: December 30, 2021
    Applicants: TARGEDYS, CENTRE HOSPITALIER UNIVERSITAIRE DE ROUEN, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), UNIVERSITÉ DE ROUEN
    Inventors: Clémentine PICOLO, Grégory LAMBERT, Romain LEGRAND, Nicolas LUCAS
  • METHOD AND DEVICE FOR DETERMINING A FLOW RATE AND/OR A CONCENTRATION OF PARTICLES OF A FLUID
    Publication number: 20210396559
    Abstract: A method for determining a flow rate and/or a concentration of particles of a fluid flowing in a chamber, which includes the steps of: producing an ultrasound beam of a given frequency with a first transducer such that all fluid components traveling through an intersection region between the ultrasound beam and the chamber are insonated by the first transducer; receiving Doppler-shifted ultrasound signals generated by the fluid components in the insonated region of the chamber with a second transducer; acquiring the ultrasound signals received by the second transducer during an acquisition time; obtaining a Doppler Power Spectrum of the acquired ultrasound signals; and determining the flow rate and/or the concentration of particles of the fluid by adjustment between, on the one hand, the obtained Doppler Power Spectrum and, on the other hand, a model of the Doppler Power Spectrum.
    Type: Application
    Filed: October 18, 2019
    Publication date: December 23, 2021
    Applicants: AENITIS TECHNOLOGIES, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, ÉCOLE SUPÉRIEURE DE PHYSIQUE ET DE CHIMIE INDUSTRIELLES DE LA VILLE DE PARIS
    Inventors: Jean PROVOST, Jérémie GACHELIN, Baptiste PIALOT, Olivier COUTURE, Emmanuel VINCENT
  • TET2 as a diagnostic and pronostic marker in hematopoietic neoplasms
    Patent number: 11203788
    Abstract: The present invention concerns an in vitro method for diagnosing a myeloid tumour or a lymphoid tumour in a subject, which comprises the step of analyzing a biological sample from said subject by (i) detecting the presence of a mutation in the Ten Eleven Translocation protein family member 2 gene (TET2) coding for the polypeptide having the sequence SEQ ID NO: 2, and/or (ii) analyzing the expression of the TET2 gene; wherein the detection of such a TET2 mutation, of the absence of expression of TET2 or of the expression of a truncated TET2 is indicative of a subject developing or predisposed to develop a myeloid tumour or a lymphoid tumour.
    Type: Grant
    Filed: April 8, 2020
    Date of Patent: December 21, 2021
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), INSTITUT GUSTAVE-ROUSSY, ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS, CENTRE HENRI BECQUEREL, UNIVERSITE PIERRE ET MARIE CURIE, UNIVERSITE PARIS-SUD
    Inventors: Franck Viguie, Olivier Bernard, Michaela Fontenay, Christian Bastard, Francois Delhommeau, William Vainchenker
  • Recombinant adeno-associated virus particle purification with multiple-step anion exchange chromatography
    Patent number: 11203740
    Abstract: The invention describes a method for obtaining purified recombinant Adeno-Associated Virus particles (rAAV), comprising performing a depth filtration of a starting material previously obtained from cells producing rAAV particles comprising a cell lysate and/or a culture supernatant, followed by a first step of anion-exchange chromatography, a second step of anion-exchange chromatography and a final step of tangential flow filtration, whereby purified recombinant Adeno-Associated Virus particles (rAAV) are provided.
    Type: Grant
    Filed: February 9, 2016
    Date of Patent: December 21, 2021
    Assignees: INSTITUT NATIONAL DE LA SANTE DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE DE NANTES, CHU NANTES, ASSOCIATION FRANCAISE CONTRE LES MYOPATHIES
    Inventor: Nicole Brument
  • Hepcidin antagonists for use in the treatment of inflammation
    Patent number: 11203753
    Abstract: The present invention relates to a hepcidin antagonist for use in the treatment of inflammatory diseases.
    Type: Grant
    Filed: March 14, 2016
    Date of Patent: December 21, 2021
    Assignees: INSERM (Institut National de la Santé et de la Recherche Médicale), Centre National de la Recherche Scientifique (CNRS), Université Paris Descartes, Université Paris Diderot—Paris 7
    Inventors: Carole Peyssonnaux, Jacques Mathieu, Sara Zumerle
  • Ex vivo generation of ?? Foxp3regulatory T cells and therapeutic uses thereof
    Patent number: 11198851
    Abstract: The present invention relates to a method for ex vivo generating and expanding ?? Foxp3+ regulatory T cells, and therapeutic uses thereof. The inventors performed the induction of Foxp3+ expression in ex vivo human induced tumor-antigen specific CD4+ TCR?? unrestricted T cells and the induction of autologous CD8-mediated T-cell responses against tumor-antigen specific FOXP3 expressing CD4+ TCR?? unrestricted T cells. The inventors developed a method to ex vivo generated and expanded antigen specific Foxp3 expressing CD3+ TCR??+ unrestricted T cells, committed to exclusively exert regulatory activity, whichever culture condition of stimulation is. In particular, the present invention relates to a method for generating ex vivo ?? Foxp3+ regulatory T cells having the following phenotype: CD3+ TCR??+ Foxp3+.
    Type: Grant
    Filed: August 4, 2017
    Date of Patent: December 14, 2021
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERE MEDICALE), MEDECINE ET INNOVATION, UNIVERSITE DE PARIS, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
    Inventors: Daniel Zagury, Helene Le Buanec, Sophie Duchez, Valerie Schiavon, Armand Bensussan
  • HOMEOPROTEINS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISORDERS
    Publication number: 20210379144
    Abstract: The present disclosure relates to the use of a homeoprotein or a recombinant vector encoding said protein for treating or preventing DNA damage and/or cellular aging. In particular, the invention concerns the use of Engrailed for the treatment of Parkinson disease.
    Type: Application
    Filed: June 16, 2021
    Publication date: December 9, 2021
    Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), COLLEGE DE FRANCE, SORBONNE UNIVERSITE
    Inventor: Alain Prochiantz
  • Method of modulating epileptogenicity in a patient's brain
    Patent number: 11191476
    Abstract: The method of modulating epileptogenicity in a brain of an epileptic patient includes: providing a virtual brain; providing a model of an epileptogenic and of a propagation zones and loading the model in the virtual brain to create a virtual epileptic brain; acquiring data of the brain of the epileptic patient; identifying, in the data, a location of at least one possible epileptogenic zone; fitting the virtual epileptic brain against the data acquired from the epileptic patient and parametrizing the at least one possible epileptogenic zone in the virtual epileptic brain as an epileptogenic zone; and simulating, within the virtual epileptic brain, the effect of a network modulation mimicking a clinical intervention of the brain of the patient.
    Type: Grant
    Filed: July 18, 2016
    Date of Patent: December 7, 2021
    Assignees: UNIVERSITE D'AIX MARSEILLE (AMU), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), ASSISTANCE PUBLIQUE—HOPITAUX DE MARSEILLE (AP-HM), INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Viktor Jirsa, Christophe Bernard, Fabrice Bartolomei, Maxime Guye
  • Lebecetin, a C-type lectin, as neovascularization inhibitor
    Patent number: 11191807
    Abstract: The present invention relates to lebecetin, a functional variant or fragment thereof, for use as neovascularization inhibitor, in particular in the treatment of neovascular diseases such as ocular diseases, cancers or inflammatory disorders with a neovascular component.
    Type: Grant
    Filed: December 12, 2017
    Date of Patent: December 7, 2021
    Assignees: SARBONNE INIVERSIÉ, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MEDICALE), INSTITUT PASTEUR DE TUNIS
    Inventors: Xavier Guillonneau, Fadoua Montassar, Naziha Marrakchi, Erij Messadi, Florian Sennlaub, José-Alain Sahel
  • Tourniquet with elastic sleeve
    Patent number: 11185337
    Abstract: The present invention relates to a tourniquet (1) comprising: • a support (2) for surrounding a first portion of a limb, • an elastic sleeve (4) to be held in a stretched position around the support (2), the support (2) preventing contraction of the elastic sleeve (4), • a grip element (8) which is movable relative to the support (2), • a drive element (6) for driving the elastic sleeve (4), when the grip element (8) is moved manually relative to the support (2), from its stretched position around the support to a blood vessel constricting position wherein the elastic sleeve (4) surrounds a second portion of the limb, adjacent to the first portion of the limb but not surrounded by the support (2), in such a way that the elastic sleeve (4) can contract by resilient return, and thus compress the second portion of the limb.
    Type: Grant
    Filed: February 16, 2018
    Date of Patent: November 30, 2021
    Assignees: SORBONNE UNIVERSITY, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) FILIX
    Inventors: Guillaume Chenegros, Nicolas Libert, Stephane Carras